Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A-induced protective ptosis versus temporary tarsorrhaphy for persistent corneal epithelial defect
TCTR20130627002Phase 2Recruiting
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Jun 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of botulinum toxin type A in corneal persistent epithelial defect (PED), sponsored by Ratchadaphiseksomphot Endowment Fund. Started Jun 2013; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
corneal persistent epithelial defect (PED)
Beyond the preview
Go deeper on TCTR20130627002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20130627002.